Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 10 | 2017 | 3481 | 0.830 |
Why?
|
| Brain Neoplasms | 15 | 2017 | 8863 | 0.680 |
Why?
|
| Magnetic Resonance Imaging | 20 | 2017 | 35421 | 0.570 |
Why?
|
| Spectrum Analysis, Raman | 3 | 2014 | 247 | 0.560 |
Why?
|
| Astrocytoma | 2 | 2015 | 790 | 0.440 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2012 | 30 | 0.430 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 195 | 0.390 |
Why?
|
| Head | 1 | 2017 | 880 | 0.390 |
Why?
|
| Cell Tracking | 1 | 2012 | 145 | 0.390 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2011 | 139 | 0.370 |
Why?
|
| Adenoma | 2 | 2011 | 2174 | 0.350 |
Why?
|
| Ciliary Body | 1 | 2009 | 173 | 0.340 |
Why?
|
| Echo-Planar Imaging | 2 | 2014 | 659 | 0.330 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1928 | 0.320 |
Why?
|
| Neuronavigation | 1 | 2009 | 167 | 0.310 |
Why?
|
| Mesencephalon | 1 | 2009 | 329 | 0.300 |
Why?
|
| Uveal Neoplasms | 1 | 2009 | 310 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 20129 | 0.280 |
Why?
|
| Melanoma | 2 | 2023 | 5510 | 0.280 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2017 | 3327 | 0.270 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 1504 | 0.270 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 1423 | 0.250 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 6773 | 0.250 |
Why?
|
| Dacarbazine | 3 | 2015 | 566 | 0.240 |
Why?
|
| Image Enhancement | 5 | 2012 | 2921 | 0.240 |
Why?
|
| Critical Care | 1 | 2017 | 2647 | 0.240 |
Why?
|
| Skin | 2 | 2017 | 4364 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2012 | 2737 | 0.220 |
Why?
|
| Pituitary Neoplasms | 1 | 2011 | 1345 | 0.210 |
Why?
|
| Deep Brain Stimulation | 1 | 2009 | 748 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 9274 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2017 | 4445 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 3 | 2012 | 1005 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 1 | 2012 | 2657 | 0.180 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2731 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2017 | 9239 | 0.160 |
Why?
|
| Algorithms | 8 | 2012 | 13881 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 20822 | 0.150 |
Why?
|
| Sarcoma | 1 | 2008 | 1897 | 0.150 |
Why?
|
| Tomography, Spiral Computed | 1 | 2017 | 280 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 512 | 0.130 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 6895 | 0.130 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 2 | 2006 | 89 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13695 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 14722 | 0.110 |
Why?
|
| Survival Rate | 3 | 2017 | 12788 | 0.110 |
Why?
|
| Female | 22 | 2023 | 380194 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2023 | 77449 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2015 | 1654 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 19905 | 0.100 |
Why?
|
| Middle Aged | 16 | 2017 | 213383 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2011 | 2250 | 0.100 |
Why?
|
| Glioma | 4 | 2013 | 3401 | 0.100 |
Why?
|
| Humans | 35 | 2023 | 744343 | 0.090 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2011 | 129 | 0.090 |
Why?
|
| Brain Chemistry | 1 | 2014 | 981 | 0.090 |
Why?
|
| Stroke | 2 | 2012 | 9981 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2017 | 63114 | 0.090 |
Why?
|
| Demyelinating Diseases | 1 | 2012 | 354 | 0.090 |
Why?
|
| Ventral Thalamic Nuclei | 1 | 2009 | 41 | 0.090 |
Why?
|
| Male | 17 | 2017 | 350118 | 0.080 |
Why?
|
| Medicine, Traditional | 1 | 2009 | 91 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2012 | 525 | 0.080 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2008 | 16 | 0.080 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2008 | 17 | 0.080 |
Why?
|
| Vagus Nerve | 1 | 2011 | 438 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2015 | 8949 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2017 | 10252 | 0.080 |
Why?
|
| Microelectrodes | 1 | 2009 | 303 | 0.080 |
Why?
|
| Brain | 9 | 2014 | 26385 | 0.080 |
Why?
|
| Microscopy | 1 | 2013 | 903 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2012 | 1100 | 0.080 |
Why?
|
| Diagnosis, Differential | 6 | 2011 | 12959 | 0.080 |
Why?
|
| ROC Curve | 1 | 2015 | 3527 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2009 | 353 | 0.080 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 405 | 0.070 |
Why?
|
| Subthalamic Nucleus | 1 | 2009 | 184 | 0.070 |
Why?
|
| Heme Oxygenase-1 | 1 | 2009 | 381 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2014 | 4042 | 0.070 |
Why?
|
| Amnesia, Anterograde | 1 | 2006 | 21 | 0.070 |
Why?
|
| Brain Diseases | 2 | 2008 | 1563 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2012 | 1534 | 0.070 |
Why?
|
| Encephalitis, Viral | 1 | 2006 | 55 | 0.070 |
Why?
|
| Neurilemmoma | 1 | 2011 | 547 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2012 | 3689 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2011 | 2297 | 0.070 |
Why?
|
| Herpesvirus 6, Human | 1 | 2006 | 95 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 1770 | 0.070 |
Why?
|
| Adult | 15 | 2015 | 214055 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2007 | 3760 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 657 | 0.060 |
Why?
|
| Brain Mapping | 3 | 2009 | 6669 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2012 | 2038 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 2002 | 0.060 |
Why?
|
| Contrast Media | 1 | 2017 | 5300 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2017 | 3679 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1180 | 0.060 |
Why?
|
| Pandemics | 1 | 2023 | 8388 | 0.060 |
Why?
|
| Quinazolines | 1 | 2010 | 1356 | 0.060 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 545 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 4034 | 0.060 |
Why?
|
| Monitoring, Intraoperative | 1 | 2009 | 957 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3616 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 627 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2007 | 547 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 18029 | 0.050 |
Why?
|
| Epidermal Cyst | 1 | 2002 | 62 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2007 | 587 | 0.050 |
Why?
|
| Brain Abscess | 1 | 2002 | 118 | 0.050 |
Why?
|
| Piperidines | 1 | 2010 | 1602 | 0.050 |
Why?
|
| Scoliosis | 1 | 2008 | 725 | 0.050 |
Why?
|
| Lipids | 1 | 2012 | 3305 | 0.050 |
Why?
|
| Artifacts | 1 | 2009 | 1904 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2008 | 1774 | 0.050 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2008 | 912 | 0.050 |
Why?
|
| Neuroglia | 1 | 2005 | 927 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 1061 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 1583 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
| Software | 1 | 2012 | 4443 | 0.040 |
Why?
|
| Disease Progression | 1 | 2014 | 13284 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 2618 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6103 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 29063 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 12354 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16689 | 0.030 |
Why?
|
| Aged | 8 | 2017 | 163280 | 0.030 |
Why?
|
| Laryngectomy | 1 | 2017 | 248 | 0.030 |
Why?
|
| Animals | 5 | 2013 | 168757 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 13989 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 21827 | 0.030 |
Why?
|
| Hematoxylin | 1 | 2013 | 64 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 72 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 11031 | 0.030 |
Why?
|
| Mice | 4 | 2013 | 81183 | 0.030 |
Why?
|
| Larynx | 1 | 2017 | 494 | 0.030 |
Why?
|
| Color | 1 | 2013 | 307 | 0.030 |
Why?
|
| Software Validation | 1 | 2012 | 59 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 53288 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 11524 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8642 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6364 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 57776 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 973 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2085 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 5686 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 40075 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 15295 | 0.020 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 66 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 5442 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 892 | 0.020 |
Why?
|
| Diverticulitis | 1 | 2010 | 171 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 733 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 2593 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 546 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 379 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 147 | 0.020 |
Why?
|
| Urban Health | 1 | 2008 | 547 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11124 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 969 | 0.020 |
Why?
|
| Peru | 1 | 2008 | 881 | 0.020 |
Why?
|
| Neurons | 1 | 2005 | 9338 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5078 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 895 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 13102 | 0.020 |
Why?
|
| Diffusion | 1 | 2006 | 833 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 72290 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2008 | 1792 | 0.010 |
Why?
|
| Pulvinar | 1 | 2003 | 22 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1344 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2252 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 2006 | 534 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1376 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2382 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1130 | 0.010 |
Why?
|
| HIV Infections | 1 | 2008 | 16718 | 0.010 |
Why?
|
| Temporomandibular Joint | 1 | 2003 | 196 | 0.010 |
Why?
|
| Wrist | 1 | 2003 | 224 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1179 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4933 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 2635 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2008 | 1320 | 0.010 |
Why?
|
| Orbit | 1 | 2003 | 426 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4217 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2007 | 1533 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4982 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 1832 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2011 | 2214 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 56430 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 9734 | 0.010 |
Why?
|
| Poverty | 1 | 2008 | 2660 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39050 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 2480 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3582 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 5172 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 4256 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 7913 | 0.010 |
Why?
|
| Biopsy | 1 | 2003 | 6756 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6234 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 5708 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2003 | 6150 | 0.000 |
Why?
|
| Child | 1 | 2008 | 77709 | 0.000 |
Why?
|
| Adolescent | 1 | 2008 | 85781 | 0.000 |
Why?
|
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_